Bioatla Net Income
| BCAB Stock | USD 0.19 0.02 10.05% |
As of the 5th of February, Bioatla shows the Mean Deviation of 7.02, risk adjusted performance of (0.08), and Standard Deviation of 10.16. Bioatla technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Bioatla Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 2.4321 | Earnings Share (1.15) | Quarterly Revenue Growth 0.316 |
| Last Reported | Projected for Next Year | ||
| Net Loss | -62.8 M | -65.9 M | |
| Net Loss | -95.8 M | -91 M | |
| Net Loss | -62.8 M | -65.9 M | |
| Net Loss | (1.65) | (1.73) | |
| Net Income Per E B T | 1.14 | 1.09 |
Bioatla | Net Income | Build AI portfolio with Bioatla Stock |
Analyzing Bioatla's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Bioatla's current valuation and future prospects.
Latest Bioatla's Net Income Growth Pattern
Below is the plot of the Net Income of Bioatla over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bioatla financial statement analysis. It represents the amount of money remaining after all of Bioatla operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bioatla's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bioatla's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (69.78 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Bioatla Net Income Regression Statistics
| Arithmetic Mean | (49,948,101) | |
| Coefficient Of Variation | (63.13) | |
| Mean Deviation | 26,231,896 | |
| Median | (28,979,000) | |
| Standard Deviation | 31,532,179 | |
| Sample Variance | 994.3T | |
| Range | 94.5M | |
| R-Value | (0.69) | |
| Mean Square Error | 549.4T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (4,334,940) | |
| Total Sum of Squares | 15908.5T |
Bioatla Net Income History
Other Fundumenentals of Bioatla
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bioatla Net Income component correlations
Bioatla Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bioatla is extremely important. It helps to project a fair market value of Bioatla Stock properly, considering its historical fundamentals such as Net Income. Since Bioatla's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bioatla's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bioatla's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. Projected growth potential of Bioatla fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bioatla assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bioatla's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bioatla should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bioatla's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Bioatla 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bioatla's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bioatla.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Bioatla on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Bioatla or generate 0.0% return on investment in Bioatla over 90 days. Bioatla is related to or competes with Celularity, PolyPid, Annovis Bio, Reviva Pharmaceuticals, Evaxion Biotech, BioXcel Therapeutics, and Generation Bio. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics f... More
Bioatla Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bioatla's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bioatla upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 66.15 | |||
| Value At Risk | (18.87) | |||
| Potential Upside | 15.28 |
Bioatla Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioatla's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bioatla's standard deviation. In reality, there are many statistical measures that can use Bioatla historical prices to predict the future Bioatla's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (2.01) | |||
| Treynor Ratio | 0.3455 |
Bioatla February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 0.3555 | |||
| Mean Deviation | 7.02 | |||
| Coefficient Of Variation | (816.03) | |||
| Standard Deviation | 10.16 | |||
| Variance | 103.27 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (2.01) | |||
| Treynor Ratio | 0.3455 | |||
| Maximum Drawdown | 66.15 | |||
| Value At Risk | (18.87) | |||
| Potential Upside | 15.28 | |||
| Skewness | (0.31) | |||
| Kurtosis | 2.75 |
Bioatla Backtested Returns
Bioatla secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13 % return per unit of risk over the last 3 months. Bioatla exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Bioatla's Risk Adjusted Performance of (0.08), mean deviation of 7.02, and Standard Deviation of 10.16 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -3.63, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bioatla are expected to decrease by larger amounts. On the other hand, during market turmoil, Bioatla is expected to outperform it. At this point, Bioatla has a negative expected return of -1.38%. Please make sure to confirm Bioatla's skewness, day typical price, and the relationship between the value at risk and rate of daily change , to decide if Bioatla performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.16 |
Insignificant reverse predictability
Bioatla has insignificant reverse predictability. Overlapping area represents the amount of predictability between Bioatla time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bioatla price movement. The serial correlation of -0.16 indicates that over 16.0% of current Bioatla price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.16 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bioatla reported net income of (69.78 Million). This is 120.45% lower than that of the Biotechnology sector and 199.61% lower than that of the Health Care industry. The net income for all United States stocks is 112.22% higher than that of the company.
Bioatla Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioatla's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bioatla could also be used in its relative valuation, which is a method of valuing Bioatla by comparing valuation metrics of similar companies.Bioatla is currently under evaluation in net income category among its peers.
Bioatla Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bioatla from analyzing Bioatla's financial statements. These drivers represent accounts that assess Bioatla's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bioatla's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.1B | 678.4M | 117.5M | 28.7M | 33.0M | 31.4M | |
| Enterprise Value | 907.0M | 438.8M | 8.5M | (19.5M) | (22.4M) | (21.3M) |
Bioatla Institutional Holders
Institutional Holdings refers to the ownership stake in Bioatla that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bioatla's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioatla's value.| Shares | Marshall Wace Asset Management Ltd | 2025-06-30 | 80.8 K | Susquehanna International Group, Llp | 2025-06-30 | 74.8 K | Magnus Financial Group Llc | 2025-06-30 | 47.2 K | Mccormack Advisors International | 2025-06-30 | 44.3 K | Alpha Cubed Investments Llc | 2025-06-30 | 41.1 K | National Asset Management Inc | 2025-06-30 | 30 K | Ubs Group Ag | 2025-06-30 | 29.6 K | Columbia Advisory Partners Llc | 2025-06-30 | 26.1 K | Commonwealth Equity Services Inc | 2025-06-30 | 25.3 K | Vanguard Group Inc | 2025-06-30 | 1.8 M | Tang Capital Management Llc | 2025-06-30 | 1.4 M |
Bioatla Fundamentals
| Return On Equity | -8.14 | ||||
| Return On Asset | -1.05 | ||||
| Current Valuation | 8.96 M | ||||
| Shares Outstanding | 64.04 M | ||||
| Shares Owned By Insiders | 11.07 % | ||||
| Shares Owned By Institutions | 28.84 % | ||||
| Number Of Shares Shorted | 4.74 M | ||||
| Price To Book | 2.68 X | ||||
| Price To Sales | 4.22 X | ||||
| Revenue | 11 M | ||||
| Gross Profit | (46.73 M) | ||||
| EBITDA | (73.02 M) | ||||
| Net Income | (69.78 M) | ||||
| Cash And Equivalents | 178.12 M | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 836 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 7.48 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (71.94 M) | ||||
| Short Ratio | 2.10 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 61 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 12.1 M | ||||
| Total Asset | 52.42 M | ||||
| Retained Earnings | (486.04 M) | ||||
| Working Capital | 36.69 M | ||||
| Net Asset | 52.42 M |
About Bioatla Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bioatla's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioatla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioatla based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bioatla offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bioatla's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioatla Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioatla Stock:Check out For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. Projected growth potential of Bioatla fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bioatla assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bioatla's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bioatla should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bioatla's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.